Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Down 23.8% in March

Dermata Therapeutics, Inc. (NASDAQ:DRMA) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 188,800 shares, a drop of 23.8% from the February 28th total of 247,700 shares. Approximately 4.7% of the company’s stock are short sold. Based on an average daily volume of 349,300 shares, the short-interest ratio is currently 0.5 days.

Dermata Therapeutics Stock Performance

Shares of Dermata Therapeutics stock traded down $0.00 during midday trading on Wednesday, reaching $1.00. 185,703 shares of the company’s stock traded hands, compared to its average volume of 1,611,095. Dermata Therapeutics has a 52 week low of $0.95 and a 52 week high of $6.67. The company’s 50 day simple moving average is $1.20 and its 200 day simple moving average is $1.30. The company has a market cap of $5.40 million, a price-to-earnings ratio of -0.06 and a beta of 0.65.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.